Contact:
At RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992
or
At the Financial
Relations Board:
Analyst Inquiries:
Leslie Loyet
312.640.6672
or
General Inquiries
Kathy Waller
312.640.6696 |
RegeneRx to Present at 17th Annual Wall Street Analyst Forum
RegeneRx to Present at 17th Annual Wall Street Analyst Forum
June 12, 2006 — Bethesda, Md
RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) announced today that J.J. Finkelstein, president and chief executive officer, will present at the Wall Street Analyst Forum in New York City on Wednesday, June 14, 2006, at 9:10 a.m. EST.
A live webcast may be accessed by visiting http://www.investorcalendar.com/CEPage.asp?ID=104915. A replay of the event will be available on the company's website at www.regenerx.com for 30 days following the presentation.
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore RegeneRx is developing TB4 as a therapeutic platform. RegeneRx holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, and septic shock. RegeneRx is currently sponsoring three Phase II chronic dermal wound healing clinical trials and has additionally targeted ophthalmic and cardiac trials in 2006 as part of its ongoing clinical development program.
For more information please visit RegeneRx's web site at www.regenerx.com
SOURCE: RegeneRx Biopharmaceuticals, Inc.  Back To 2006 Press Release Archives
|
